Mumbai: There will no longer be a need to bear the pain of injections for the number of type-2 diabetes patients in the country. Novo Nordic India has now launched the world’s first Semaglutide DLP 1 RA in tablet form for type 2 diabetes patients. This medicine can prove to be a game changer for patients suffering from diabetes.
Till now, injection was the only option for diabetics. It was painful to inject daily. Keeping this in view, Novo Nordix India has reduced the suffering of patients by launching the drug in oral and tablet form. The company has developed the oral formulation of Semaglutide after 15 years of continuous research. Oral semaglutide has been recognized by the Drug Controller of India only last year.
read also
Proven to be a game changer
Glimesim is proving to be a game changer in the control and management of adults with type 2 diabetes. Vikrant Shrotia, Corporate Vice Chairman and Managing Director, Novo Nordigs India, said this drug has the power to bring about a paradigm shift in type 2 patients. We are thrilled with the launch of the drug.
LP1 is a naturally occurring hormone. It plays an important role in maintaining normal blood glucose level. Peptide and protein based biologic drugs are proving to be very effective.
-Doctor. Shashank Joshi, Endocrinologist, Lilavati Hospital, Mumbai